The 2009 influenza A H1N1 pandemic placed unprecedented demands on antiviral drug resources and the vaccine industry. Carrageenan, an extractive of red algae, has been proven to inhibit infection and multiplication of various enveloped viruses. The aim of this study was to examine the ability of κ-carrageenan to inhibit swine pandemic 2009 H1N1 influenza virus to gain an understanding of antiviral ability of κ-carrageenan. It was here demonstrated that κ-carrageenan had no cytotoxicity at concentrations below 1000 μg/ml. Hemagglutination, 50% tissue culture infectious dose (TCID 50 ) and cytopathic effect ( Immunofluorescence assay and Western blot showed that κ-carrageenan also inhibited SW731 protein expression after its internalization into cells. These results suggest that κ-carrageenan can significantly inhibit SW731 replication by interfering with a few replication steps in the SW731 life cycles, including adsorption, transcription, and viral protein expression, especially interactions between HA and cells. In this way, κ-carrageenan might be a suitable alternative approach to therapy meant to address anti-IAV, which contains an HA homologous to that of SW731.
Introduction
In late April 2009, the emergence of the pandemic H1N1/2009 virus in North America caused a pandemic, which attracted a great deal of attention from all over the world [1, 2] . Some viruses were amplified in MDCK cells. The titers were determined to TCID 50 using IFA. For viral infection, viral propagation solutions were diluted in DMEM and added to cells at the indicated multiplicity of infection (MOI). After adsorption for 60 min at 4°C, viral inoculum was removed and cells were maintained in infecting media (DMEM) containing 2 μg/ml tosylsulfonyl phenylalanyl chloromethyl ketone (TPCK)-trypsin (Worthington Biochemical, Lakewood, NJ, U.S.), at 37°C in 5% CO 2 .
Cytotoxicity assays
The cytotoxicity of κ-carrageenan was measured using the MTT assay (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide; Sigma-Aldrich, U.S.). MDCK cells were seed at a density of 1×10 4 cells per well of a 96-well plate in 100 μl of complete growth medium overnight.
MDCK cells were exposed to different concentrations of compounds in triplicate at 37°C in 5% CO 2 . Then, 48 h later, 10 μl of PBS containing MTT (final concentration: 0.5 mg/ml) was added to each well. After 4 h of incubation at 37°C, the supernatant was removed and 200 μL of DMSO was added to each well to solubilize the formazan crystals. After vigorous shaking, absorbance values were measured in a microplate reader (Bio-Rad, U.S.) at 570 nm.
Hemagglutination (HA) assays
Then 25 μl SW731, CA04, PR8, WSN, and ZB07 viruses were serially diluted in the blood clot count plate. Then each sample was mixed with 25 μl of 1% chicken red blood cells (RBC) and incubated at room temperature. Then, 30 min later, the HA titers were determined.
Viral titer measurement
The viral titer was measured with the TCID 50 . Briefly, the viral solution was serially diluted 10-fold in DMEM. A 100 μl aliquot of each diluted sample was added to the wells of 96-well plates, containing monolayer MDCK cells. Cells were cultured for 36-48 h at 37°C in 5% CO 2 . NP protein positive wells in IFA were considered positive. The titer was calculated using a previously described method [19] . All experiments with virus were performed under biosafety level 2 (BSL-2) conditions with investigators wearing appropriate protective equipment in compliance with general biosafety standards for microbiological and biomedical laboratories of Ministry of Health of the People's Republic of China (WS 233-2002) .
CPE inhibition assay
Then 2.5 × 10 5 MDCK cells were seeded in 96-well plates and maintained in DMEM plus 10% FBS overnight. After infection with SW731 at an MOI of 1, the cells were treated with κ-carrageenan at indicated concentrations and incubated at 37°C in 5% CO 2 . Then, 48 h later, the CPE was determined as previously described. Briefly, MDCK cells were fixed with 4% formaldehyde for 20 min at room temperature. After removal of the formaldehyde, the cells were stained with 0.1% crystal violet for 30 min and then washed and dried. Then the plates were solubilized with methanol and the intensity of crystal violet staining for each well measured at 570 nm. The concentration required for a test compound to reduce the CPE of the virus by 50% (IC50) was determined.
Quantitative real-time PCR (qRT-PCR)
Total RNA was extracted from SW731 infected MDCK or RAW cells using a TRIgene (GeneStar, China), and treated with DNase I (Promega, U.S.) to remove the contaminating DNAs. Then 1 μg of total RNA was reverse-transcribed into cDNA using a GoScript reverse transcription system (Promega, U.S.) in a 20 μl reaction mixture. The cDNA was analyzed by qRT-PCR using SYBR green Master I (Roche, U.S. s. The final step was to obtain a melt curve for the PCR products to determine the specificity of amplification. All controls and infected samples were carried out in triplicate on the same plate. Relative mRNA abundances were calculated using the 2 -ΔΔCt method with β-actin as a reference and plotted as fold change relative to mock-control samples [20] .
Indirect immunofluorescence assay
MDCK cells were washed with PBS and fixed with 4% paraformaldehyde for 10 min. Then cells were permeabilized with 0.5% (v/v) Triton X-100 in PBS for 10 min before incubated with 3% BSA/PBS for 1 h at 37°C. Cells were washed and incubated with anti-NP antibody for overnight at 4°C. After three rounds of washing, the cells were incubated with FITC-labeled secondary antibody for 1 h at 37°C. Cells were examined with an inverted fluorescence microscope (Olympus, Japan).
Western blot analysis
MDCK cells were lysed in RIPA containing 20 mM Tris base-HCl (pH 7.5), 150 mM NaCl, 1.0 mM EDTA (pH 8.0), 1.0 M EGTA (pH 8.0), 0.1% SDS, 0.5% DOC (Sigma, U.S.), 1% NP-40 (Sigma, U.S.), protease inhibitor cocktail (Roche, U.S.), and phosphatase inhibitor cocktail (Roche, U.S.). Proteins were separated by SDS-PAGE under reducing conditions and analyzed by Western blotting using anti-NP, anti-GAPDH antibodies and HRP-labeled secondary antibodies [21] .
Hemagglutination Inhibition assay
Then 25 μl of serially diluted SW731, SW26, CA04, WSN, LY08, and ZB07 virus were incubated with the same volume of PBS (Mock) or serially diluted κ-carrageenan for 20 min. Then each sample was mixed with 50 μl of 1% RBC at room temperature. After 30 min, the concentrations of κ-carrageenan inhibiting HA activity were measured.
NA enzyme assay
NA activity was analyzed using a method which has been previously described [22] . Briefly, SW731 virus stock was diluted to 10 5 pfu/50 μl with 33 mM MES (2-[N-morpholino]ethanesulfonic acid) buffer pH 6.5 containing 4 mM CaCl2 in the presence or absence of κ-carrageenan. NA activity assay was carried out at 37°C using methylumbelliferyl-N-acetylneuraminic acid (MUNANA) as substrate and luorescence was quantified on a fluorimeter.
Statistics
All data analyses were performed using SPSS 16.0. Independent sample t-testing was used to detect significant differences between compound-treated groups and control groups. P values < 0.05 were considered significant. Data are presented as mean ± SEM.
Results

κ-carrageenan treatment does not show harmful effects on cell metabolic activity
Because the use of drugs targeting cellular factors raises concerns about side effects on the host cells, antiviral-acting concentrations of κ-carrageenan were assessed for cytotoxicity. MTT assays were performed after 48 h of κ-carrageenan treatment at the indicated concentrations to investigate the impact of κ-carrageenan treatment on the metabolism of MDCK cells. There was no observable difference in metabolic activity of MDCK cells treated with concentration of 62.5-250 μg/ml κ-carrageenan and untreated cells (CC 50 > 1000 μg/ml) (Fig 1) . But the concentration of 1000 μg/ml κ-carrageenan treatment led to a reduced relative metabolic activity 62% (Fig 1) .
κ-carrageenan specifically inhibits SW731 multiplication in MDCK cells
To investigate the in vitro anti-IAV activity of κ-carrageenan, MDCK cells were first infected with different strains of IAV (SW731, CA04, PR8, WSN, and ZB07) at an MOI of 0.1 or 1 and then treated with κ-carrageenan at the indicated concentrations. After 24 h, virus titers of the supernate were determined using TCID 50 and HA assays. Fig 2A-2D show that the κ-carrageenan could markedly decrease the virus titer of SW731 and CA04 in a dose-dependent manner, while, PR8, WSN and ZB07 are not sensitive to κ-carrageenan. Only 250 μg/ml κ-carrageenan showed even a slight inhibitory effect on viral titer of WSN with a lower initial MOI of 0.1. CPE inhibition was performed to testify the protective effect of κ-carrageenan on MDCK from SW731. Consistent with the viral titer assay, it was here observed that the cell viability was significantly promoted by κ-carrageenan in a dose-dependent fashion ( Fig 2E) with an EC 50 value of 89.57±2.1 μg/ml. In this way, κ-carrageenan specifically suppressed the replication of SW731 instead of the classical H1N1 strain PR8, WSN and avian influenza virus ZB07 in MDCK cells.
κ-carrageenan interfered with extracellular and intracellular steps in SW731 replication
To determine which steps of SW731 replication are involved in inhibitory actions of κ-carrageenan, κ-carrageenan was added to MDCK cells for an 8 h period of overall viral adsorption (0 h), internalization (1 h), early replication (2-6 h), and release (8 h). Then, 24 h p.i., the inhibitory effect was assessed with TCID 50 assays. As shown in Fig 3 , viral titers were markedly lower when κ-carrageenan were added at 0, 1, 2, 4, and 6 h.p.i., and κ-carrageenan could not effectively inhibit SW731 multiplication when κ-carrageenan were added at 8 h.p.i. No difference was observed among the viral titers when κ-carrageenan was added at 0, 1, 2, 4, and 6 h.p.i. These data indicate that a few of the extracellular and intracellular steps of SW731 replication were targets of κ-carrageenan.
infected with SW731 at an MOI of 1 and then treated with κ-carrageenan at the indicated concentration after removal of the viral inoculum. After 48 h, CPE inhibition was determined by CPE assay. Results were analyzed with the independent sample t test (n = 3 
κ-carrageenan directly inhibited SW731 adsorption and internalization
To further elucidate the mechanism underlying the anti-SW731 activity of κ-carrageenan, we also investigated whether κ-carrageenan elicits its inhibitory actions directly on virus particles, cell receptor, viral adsorption or internalization. MDCK cells were treated with κ-carrageenan at four different conditions, pretreated-SW731, pretreated-cells, during adsorption, and afteradsorption. After 24 h viral titers in the culture media were determined by TCID 50 assay. Fig 4A shows that pretreated-SW731 , SW731 during adsorption, and SW731 after adsorption could all significantly decrease the viral titer in all samples except pretreated cells, suggesting that κ-carrageenan could interfere with binding of SW731 and MDCK by targeting the virus instead of MDCK cells, and blocking internalition. In other cases, both pretreatment-virus and adsorption groups showed significantly lower viral titers than the after-adsorption group, indicating that κ-carrageenan preferentially targets adsorption steps. No difference was observed between the pretreatment-virus and adsorption group, suggesting that κ-carrageenan did not inactivate viral particles. In addition, the number of NP-positive cells in the IFA assay and comparison of mRNA levels confirmed this deduction (Fig 4B and 4C) .
To further assess the inhibitory effect of κ-carrageenan on adsorption and internalization, the viral RNA (vRNA) levels were detected in groups treated with or without κ-carrageenan during adsorption and internalization. Fig 4D shows that the vRNA levels of NP in both adsorption and internalization groups treated with κ-carrageenan were significantly lower than in control groups. Taken together, these results suggest that κ-carrageenan had inhibitory actions directly on viral adsorption via target the viral particles instead of cells receptor, and internalization.
κ-carrageenan specifically inhibited SW731 binding to its sialic acid receptor
According to the data shown above, κ-carrageenan interfered with adsorption. It was here determined whether κ-carrageenan could inhibit the binding of HA to its receptors, Neu5Aca2-6Gal-terminated sugar chains. The HA titers of SW731 were markedly reduced by κ-carrageenan in a dose-dependent manner (Fig 5A) . To assess the specificity of this inhibitive effect, hemagglutination inhibition assays were also performed on several other influenza viruses. No difference in κ-carrageenan-treated virus PR8, WSN, ZB07, or LY08 was detected in response to PBS treatment, but κ-carrageenan can significantly decrease the HA titer of CA04 (Fig 5B  and 5C ), which contained a HA sharing 99% amino acid sequence with SW731 (Fig 5D) . HA binding of SW26, which has a HA close to SW731 in evolutionary distance, was also slightly blocked by κ-carrageenan at concentration of 500 μg/ml (Fig 5A-5D ). These data together indicate that κ-carrageenan specifically inhibited HA of SW731 binding to its sialic acid receptor.
Considering that κ-carrageenan may interact specifically with glycans on the HA protein, we analyzed the potential glycosylation site patterns on HA of 7 strains. As shown in Table 1 and S1 Fig, five potential glycosylation sites at positions 27, 28, 40, 304 and 498 on the stalk were quite conserved in all strains analyzed. There are six potential glycosylation sites in HAs of PR8, ZB07, and LY08, and five in HAs of SW26 and WSN. Only HAs of SW731 and CA04 contain 7 potential glycosylation sites, including two extra carbohydrate attachment sites at 104 and 293 on the head region of HA1, which are not present in other analyzed strains (Table 1) . Glycans on glycosylation sites 104 and 293 are close to the receptor binding pocket and the proteolytic activation site of HA, respectively, and might be involved in the inhibitory effect of κ-carrageenan on SW731 binding to its sialic acid receptor.
To determine whether virus release is modulated by κ-carrageenan, we measured the NA K m and V max values by using the fluorogenic substrate 2 0 -(4-methylumbelliferyi)-α-d-N-acetylneuraminic acid. The K m values indicated that the κ-carrageenan treatment resulted in a slight (Table 2) . Similarly, V max , which was determined by both the specific activity and the amount of enzyme in the reaction mixture, was also little lower for κ-carrageenan treated SW731 than untreated SW731. However, no significant difference was observed in both K m and V max values suggesting that the effect of κ-carrageenan on virus release was not significant.
κ-carrageenan also inhibited SW731 viral mRNA and protein expression after internalization
To further study the effect of κ-carrageenan on the replication after internalization, MDCK cells were treated with κ-carrageenan after SW731 infection. After 8 h, total RNA was extracted with infective media containing 250 μg/ml of κ-carrageenan for 1h at 37°C. Then cells were washed with PBS and maintained in compound free infective media for 24 h. Viral titers were determined in a series of TCID50 assays. The mRNA levels and NP-positive cells were detected using qRT-PCR and immunofluorescence staining, respectively. (D) MDCK cells were infected with SW731 (MOI = 3) by 2 different treatment conditions. (i) Adsorption: MDCK cells were incubated with SW731 in the presence or absence (control) of κ-carrageenan at concentration of 250 μg/ml. One hour later, the media were removed and total RNA was isolated.
(ii) Internalization: MDCK cells were incubated with SW731 at 4°C for 1 h. After removal of the inoculation, the cells were overlaid with infective media in the presence or absence of κ-carrageenan at concentration of 250 μg/ml at 37°C for 1 h, after treatment with protease K for 5 min, total RNA was extracted and analyzed using qRT-PCR. Results were analyzed using the independent sample t test. Values are means ± SEM (n = 3). Significance: *P < 0.05 vs. nondrug treated control group; **P < 0.005 vs. nondrug treated control group; # P < 0.05 vs. after adsorption group. Results are representative of two independent experiments. doi:10.1371/journal.pone.0126577.g004 for qRT-PCR assay. Current data showed that κ-carrageenan treatment reduced SW731 NP mRNA levels to about 9% that of control cells (Fig 6A) . SW731 NS1 mRNA levels also decreased to 15% that of untreated control cells after κ-carrageenan treatment (Fig 6A) .
The effect of κ-carrageenan on SW731 protein expression was also assessed with Western blot and indirect immunofluorescence assays. MDCK cells were first infected with SW731 (MOI = 3.0) and then treated with κ-carrageenan at a concentration of 250 μg/ml after viral internalization. After 8 h, viral NP protein expression was examined using Western blot and indirect immunofluorescence assays. Fig 6B shows that, in κ-carrageenan-treated MDCK cells, the NP protein level decreased significantly, to 10% that of the control group. No detectable band was found in the mock group. Consistent with the Western blot analysis, indirect immunofluorescence assay showed that almost 95% of the cells in the SW731-infected group not subjected to κ-carrageenan treatment were NP-positive (Fig 6C, a and b) , but only 5% cells accumulatin the κ-carrageenan treatment group were (Fig 6C, c and d) . No NP-positive cells were detected in mock-treated MDCK cells (Fig 6C, e and f) . These data suggested that κ-carrageenan could also inhibit SW731 mRNA and protein expression after viral internalization.
Discussion
In this report, it was demonstrated that κ-carrageenan, a sulfated polysaccharide extract of red algae, could inhibit replication of SW731 virus by specially interfering with binding of HA to MDCK cells, suppressing mRNA and protein expression after internalization in vitro. This indicates that κ-carrageenan may be suitable for use against H1N1/2009 and other viruses containing the HA of H1N1/2009. Previous reports showed that ι-carrageenan polysaccharides can inhibit replication of HPV [9] , influenza A H1N1 virus [15] , dengue virus [6] , and HRV [8] by blocking the binding of virus to cells. However, Wei Wang et al. demonstrated that κ-carrageenan oligosaccharide suppressed the influenza A H1N1 virus multiplication by directly inactivating viral particles, inhibiting transcription, and protein expression instead of interfering with adsorption [14] . In the current study, adsorption, internalization, transcription, and protein expression of SW731 were all targets of κ-carrageenan, especially the adsorption. Previous reports showed that the inhibitory effect of κ-carrageenan oligosaccharide on WSN was comparable to that observed in PR8 [14] . However, we observed that WSN viral titer was only slightly decreased by κ-carrageenan polysaccharides at a concentration of 250 μg/ml and a low MOI of 0.1. No decrease in PR8, ZB07 viral titer was observed in supernate of MDCK treated with the indicated concentrations of κ-carrageenan polysaccharides. These data suggest that inhibitory effect of κ-carrageenan polysaccharides is strain-specific among H1N1 viruses. Κ-carrageenan polysaccharide and oligosaccharide had different effects on the same influenza virus strain, which might be due to molecular weight and different levels of cell permeability.
Sulfated polysaccharide p-KG03, derived from microalga, Gyrodinium impudium, have also been found to inhibit influenza H1N1 virus attachment by interfering with HA and cells [23] . Consistent with this, current data showed that HA of SW731 was inhibited by κ-carrageenan polysaccharide in a dose-dependent manner. The CA04 virus, which contains an HA closely homologous to that of SW731, was also blocked in HA assay. However, κ-carrageenan polysaccharide only slightly decreased the HA titer of SW26 at concentration of 500 μg/ml. PR8, WSN, LY08, and ZB07 HA titer were not influenced by κ-carrageenan polysaccharide. In addition, the pretreated cells could not decrease the SW731 viral titer. These results indicate that κ-carrageenan polysaccharide might specifically target the SW731 HA instead of blocking the receptor on cells. The groups pretreated with SW731 and adsorption showed comparable viral titers and mRNA and protein levels, which suggest that κ-carrageenan may interact solely with HA of SW731 without inactivating viral particles.
Glycans near the proteolytic activation site of HA modulate HA0 cleavage and influence the infectivity of influenza virus [24] . Viral receptor binding also requires HA glycosylation [25] . Our analysis of HA sequences revealed that SW731 and CA04 contain two extra carbohydrate attachment site at 104 on the head region of HA1, and 293 close to the proteolytic activation site of HA compared with the rest of strains. However, whether κ-carrageenan interfere with adsorption and internalization via binding with the glycans at positions 104 or 293 still need further research.
Our Figs 3 and 4 demonstrated that internalization of SW731 was blocked by κ-carrageenan. However, whether the membrane fusion is influenced by κ-carrageenan is not clear. Given the optimal pH of fusion for the different viruses are not the same. The influence of κ-carrageenan on pH optima of SW731 is also a potential cause for replication inhibitory effect.
In addition to blocking the adsorption and internalization, κ-carrageenan also inhibits transcription and protein expression. Low-molecular-weight carrageenan can enter MDCK cells and target several of the intracellular steps of the viral life cycle [14] . However, high-molecularweight carrageenan has poor permeability and instead targets the attachment rather than intracellular steps [26] . The κ-carrageenan used here included both low-and high-molecular-weight κ-carrageenan. The inhibitory effect on mRNA transcription and protein expression could be due to the interference of polymerase activity by low-molecular-weight κ-carrageenan in cells. However, the high-molecular-weight κ-carrageenan can interact directly with the HA of SW731 to rob the virus of its ability to infect cells.
The intracellular events, caused by κ-carrageenan, indicate that κ-carrageenan might influence uncoating, nucleus import, nucleus export, or host antiviral innate immune response. Bae et al. and Yim et al. reported that sulfated polysaccharides can activate nitric oxide production in a JNK-dependent manner and stimulate the production of cytokines, such as interleukin-1 (IL-1), IL-6, and TNF-α in macrophages [27, 28] . Zhou Ge-fei et al. demonstrated that κ-carrageenan could also increase NO production in murine peritioneal macrophages [29] . As shown in S2 Fig, the κ- carrageenan could decrease the IL-6 and TNF-α mRNA levels but promote the IL-1β mRNA synthesis with or without SW731 infection. These data indicate that κ-carrageenan may also regulate the signaling pathways involved in cytokine production. However, the effect of κ-carrageenan on cytokine synthesis was not observed in A549 cells (data not shown), which imply that CPE inhibitory effect of κ-carrageenan is not via blocking host cytokines.
Considering that the higher concentration (EC 50 value = 89.57±2.1 μg/ml) for effectiveness compared with Ribavirin (EC 50 value = 8.3 μg/ml) may limit its application, further separation and purification of certain molecular-weight κ-carrageenan for anti-H1N1/2009 viruses research will be needed.
In summary, these results suggest that κ-carrageenan is a safe and effective means of inhibiting SW731 virus infection in vitro. Research into the underlying mechanism showed that κ-carrageenan inhibited replication mainly by specifically blocking the binding of HA to MDCK cells, internalization, mRNA and protein expression instead of blocking host cell receptor and viral release. κ-carrageenan is a promising antiviral candidate for the treatment of influenza H1N1/2009 viruses and other strains containing the homologous HA.
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